200’S Series Novel Combinations (Dopamine Pathway) is under clinical development by Alto Neuroscience and currently in Phase I for Unspecified Psychiatric Disorders. According to GlobalData, Phase I drugs for Unspecified Psychiatric Disorders have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how 200’S Series Novel Combinations (Dopamine Pathway)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
200’S Series Novel Combinations (Dopamine Pathway) overview
The drug candidates are under development for the treatment of neuropsychiatric diseases and neurodegenerative diseases. They target dopamine pathway.
Alto Neuroscience overview
Alto Neuroscience is a clinical-stage biopharmaceutical company that focuses on developing precision medicines for neuropsychiatric care. Its main activities involve leveraging AI-driven brain biomarkers to match patients with appropriate psychiatric drugs. The company’s products include a pipeline of clinical-stage medicines targeting mental health conditions such as depression and post-traumatic stress disorder. Alto Neuroscience’ products are designed for patients suffering from mental health disorders, aiming to improve treatment outcomes by identifying individuals likely to respond to specific therapies. It serves throughout the US. Alto Neuroscience is headquartered in Los Altos, California, the US.
For a complete picture of 200’S Series Novel Combinations (Dopamine Pathway)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
